home / stock / qlgn / qlgn news

QLGN News and Press, Qualigen Therapeutics Inc. From 05/21/24

Stock Information
Company Name: Qualigen Therapeutics Inc.
Stock Symbol: QLGN
Market: NASDAQ
Website: qualigeninc.com
Menu
QLGN QLGN Quote QLGN Short QLGN News QLGN Articles QLGN Message Board
Get QLGN Alerts

News, Short Squeeze, Breakout and More Instantly...
QLGN - Expected US Company Earnings on Tuesday, May 21st, 2024

CXApp Inc. (CXAI) is expected to report for quarter end 2024-03-31 Purple Biotech Ltd. (PPBT) is expected to report $-0.15 for Q1 2024 AutoZone Inc. (AZO) is expected to report $35.72 for Q3 2024 Turkcell Iletisim Hizmetleri AS (TKC) is expected to report for Q1 2024 Orkla ASA ADR...
QLGN - Marizyme Enters Into Co-Development Agreement With Qualigen Therapeutics for the Commercialization of FDA-Cleared DuraGraft(TM)

JUPITER, FL, April 16, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Marizyme, Inc. ("Marizyme", OTCQB: MRZM) announces today a Co-Development Agreement (the “Agreement”) with Qualigen Therapeutics, Inc. (“Qualigen”) (NASDAQ: QLGN ) to a...

QLGN - Qualigen Therapeutics' Novel Direct Pan-RAS Inhibitors Presented at American Association of Cancer Research (AACR) 2024 Annual Meeting

Poster Includes Preclinical Data on Novel Direct Pan-RAS Inhibitors CARLSBAD, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN) today announces a poster presentation on its preclinical No...

QLGN - Qualigen Therapeutics Announces Poster Featuring Positive Early Clinical Experience with QN-302, a Novel First-in-Class G-Quadruplex Experimental Anti-Cancer Drug, at the American Association of Cancer Research (AACR) 2024 Annual Meeting

CARLSBAD, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or the “Company,” Nasdaq: QLGN) today announces that a poster featuring its early clinical experience with a novel first-in-class G-Quadruplex experimental anti-cancer drug, ...
QLGN - Expected earnings - Qualigen Therapeutics Inc.

Qualigen Therapeutics Inc. (QLGN) is expected to report $-0.92 for Q3 2023

QLGN - Qualigen Therapeutics Provides Corporate Update for Third Quarter and To Date 2023

Initiated dosing of three patients in first cohort of Phase 1 clinical trial of QN-302 for treatment of advanced or metastatic solid tumors Phase 1a patient recruitment ongoing; company anticipates sharing update on safety and preliminary efficacy in second quarter of 2024 Expect ...

QLGN - Qualigen Therapeutics Announces First Patient Dosed in the Phase 1a Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors

CARLSBAD, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, announces today that the first patient in the Phase 1a...
QLGN - Poster Highlighting Qualigen Therapeutics' Pan-RAS Inhibitor Platform Presented at AACR Special Conference: Advances in Breast Cancer

Poster Includes Preclinical Data on Pan-RAS Compounds Demonstrating Inhibition in Breast Cancer Models CARLSBAD, Calif., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a clinical-stage therapeutics company focused on developing treatments for adult an...

QLGN - Qualigen Therapeutics Presents Scientific Data on QN-302 at AACR Special Conference: Pancreatic Cancer 2023

Two p osters include data on potential clinical biomarkers and transcriptomic data associated with QN-302’s mechanism of action CARLSBAD, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a clinical-stage th...

QLGN - Qualigen Therapeutics Partners with TD2 for Phase 1 Clinical Development of QN-302 for the Treatment of Advanced or Metastatic Solid Tumors

CARLSBAD, Calif., Aug. 17, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, announced today it is partnering with Translational Dr...
Previous 10 Next 10